ES2980114T3 - Formulaciones - Google Patents

Formulaciones Download PDF

Info

Publication number
ES2980114T3
ES2980114T3 ES18800355T ES18800355T ES2980114T3 ES 2980114 T3 ES2980114 T3 ES 2980114T3 ES 18800355 T ES18800355 T ES 18800355T ES 18800355 T ES18800355 T ES 18800355T ES 2980114 T3 ES2980114 T3 ES 2980114T3
Authority
ES
Spain
Prior art keywords
lipid
cases
rna
sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18800355T
Other languages
English (en)
Spanish (es)
Inventor
Kristy Wood
Noah Gardner
Ruchi Shah
Stephen Scully
Ramsey Majzoub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellia Therapeutics Inc
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Application granted granted Critical
Publication of ES2980114T3 publication Critical patent/ES2980114T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES18800355T 2017-09-29 2018-09-28 Formulaciones Active ES2980114T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566240P 2017-09-29 2017-09-29
PCT/US2018/053559 WO2019067992A1 (fr) 2017-09-29 2018-09-28 Formulations

Publications (1)

Publication Number Publication Date
ES2980114T3 true ES2980114T3 (es) 2024-09-30

Family

ID=64267891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18800355T Active ES2980114T3 (es) 2017-09-29 2018-09-28 Formulaciones

Country Status (30)

Country Link
US (1) US20230140670A1 (fr)
EP (2) EP3688162B1 (fr)
JP (3) JP7284179B2 (fr)
KR (2) KR20200079497A (fr)
CN (1) CN111406108A (fr)
AR (1) AR113031A1 (fr)
AU (2) AU2018338915C1 (fr)
BR (1) BR112020006300A2 (fr)
CA (1) CA3077413A1 (fr)
DK (1) DK3688162T3 (fr)
EA (1) EA202090868A1 (fr)
ES (1) ES2980114T3 (fr)
FI (1) FI3688162T3 (fr)
HR (1) HRP20240627T1 (fr)
HU (1) HUE066630T2 (fr)
IL (2) IL320823A (fr)
LT (1) LT3688162T (fr)
MX (2) MX2020007148A (fr)
MY (1) MY204993A (fr)
PH (1) PH12020552306A1 (fr)
PL (1) PL3688162T3 (fr)
PT (1) PT3688162T (fr)
RS (1) RS65493B1 (fr)
SA (1) SA520411636B1 (fr)
SG (1) SG11202002653UA (fr)
SI (1) SI3688162T1 (fr)
SM (1) SMT202400172T1 (fr)
TW (1) TWI833708B (fr)
UA (1) UA129257C2 (fr)
WO (1) WO2019067992A1 (fr)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CA3116576A1 (fr) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipides pour l'administration de nanoparticules lipidiques d'agents actifs
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
AU2020248337A1 (en) * 2019-03-28 2021-11-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
JP7631215B2 (ja) * 2019-03-28 2025-02-18 インテリア セラピューティクス，インコーポレイテッド Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (fr) 2019-06-13 2020-12-17 The General Hospital Corporation Pseudo-particules virales endogènes humaines génétiquement modifiées et leurs méthodes d'utilisation en vue d'une administration à des cellules
WO2021008708A1 (fr) * 2019-07-18 2021-01-21 Biontech Rna Pharmaceuticals Gmbh Procédé de détermination d'au moins un paramètre d'une composition d'échantillon comprenant un acide nucléique, tel que de l'arn, et éventuellement des particules
JP7759311B2 (ja) 2019-07-19 2025-10-23 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー リコンビナーゼ組成物及び使用方法
CN114901253A (zh) * 2019-08-14 2022-08-12 爱康泰生治疗公司 用于递送核酸的改进的脂质纳米颗粒
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
EP4073249A1 (fr) * 2019-12-11 2022-10-19 Intellia Therapeutics, Inc. Arn guides modifiés pour édition de gènes
BR112022015380A2 (pt) 2020-02-07 2022-09-27 Intellia Therapeutics Inc Composições e métodos para edição de gene de calicreína (klkb1)
CN116209756A (zh) 2020-03-04 2023-06-02 旗舰先锋创新Vi有限责任公司 调控基因组的方法和组合物
MX2022012683A (es) 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
CA3181340A1 (fr) 2020-04-28 2021-11-04 Intellia Therapeutics, Inc. Procedes d'administration de cellules in vitro
IL298362A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
EP4153223A1 (fr) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions immunogènes et leurs utilisations
WO2021243301A2 (fr) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Compositions à base de trem et procédés associés
KR20230029685A (ko) 2020-05-29 2023-03-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Trem 조성물 및 이에 관련된 방법
CA3189601A1 (fr) 2020-07-24 2022-01-27 The General Hospital Corporation Pseudo-particules virales ameliorees et leurs methodes d'utilisation pour l'administration a des cellules
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤
WO2022115645A1 (fr) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Nanoparticules lipidiques utilisées pour l'administration d'acides nucléiques, et méthodes d'utilisation associées
MX2023006878A (es) 2020-12-11 2023-07-31 Intellia Therapeutics Inc Composiciones y métodos para reducir el mhc de clase ii en una célula.
IL303506A (en) 2020-12-11 2023-08-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing involving deamination
CR20230320A (es) 2020-12-23 2023-10-23 Intellia Therapeutics Inc Composiciones y métodos para reducir los hla-a en una célula
WO2022140587A1 (fr) 2020-12-23 2022-06-30 Intellia Therapeutics, Inc. Compositions et procédés pour modifier génétiquement le ciita dans une cellule
IL303886A (en) 2020-12-23 2023-08-01 Flagship Pioneering Inc Compositions of modified trems and uses thereof
CN116848235A (zh) 2020-12-30 2023-10-03 因特利亚治疗公司 工程化t细胞
US20240122865A1 (en) * 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
IL307740A (en) 2021-04-17 2023-12-01 Intellia Therapeutics Inc DNA-dependent protein kinase inhibitors and their compositions and uses
WO2022261292A1 (fr) 2021-06-10 2022-12-15 Intellia Therapeutics, Inc. Arn guides modifiés comprenant un lieur interne pour l'édition de gènes
KR20240038705A (ko) 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
EP4377457A1 (fr) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Compositions de trem et leurs utilisations
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
MX2024003262A (es) 2021-09-17 2024-06-19 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para producir poliribonucleotidos circulares.
CA3235625A1 (fr) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vi, Llc Compositions et procedes de purification de polyribonucleotides
US20240415980A1 (en) 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CA3237303A1 (fr) 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Polynucleotides, compositions et methodes pour l'edition genomique
EP4436984A1 (fr) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Compositions immunogènes de coronavirus et leurs utilisations
CN118401544A (zh) 2021-11-24 2024-07-26 旗舰创业创新六公司 水痘-带状疱疹病毒免疫原组合物及其用途
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
EP4441074A2 (fr) 2021-12-03 2024-10-09 The Broad Institute, Inc. Compositions et méthodes pour administration in vivo efficace
EP4453201A1 (fr) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
KR20240118881A (ko) 2021-12-23 2024-08-05 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
CA3242731A1 (fr) 2022-02-02 2023-08-10 Regeneron Pharmaceuticals, Inc. Insertion d'anti-tfr:gaa et d'anti-cd63:gaa pour le traitement de la maladie de pompe
WO2023178425A1 (fr) 2022-03-23 2023-09-28 Nanovation Therapeutics Inc. Nanoparticules lipidiques à haute teneur en stérol
WO2023185697A2 (fr) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions et méthodes pour le traitement de l'amyloïdose de la transthyrétine
WO2023184038A1 (fr) 2022-04-01 2023-10-05 Nanovation Therapeutics Inc. Procédé d'administration d'arnm et composition associée
WO2023196634A2 (fr) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
EP4511397A1 (fr) 2022-04-19 2025-02-26 Intellia Therapeutics, Inc. Compositions de récepteurs antigéniques chimériques et utilisations
WO2023212677A2 (fr) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification de zones de sécurité extragéniques spécifiques de tissu pour des approches de thérapie génique
CA3257006A1 (fr) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs
US20250302998A1 (en) 2022-05-09 2025-10-02 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
TW202409283A (zh) 2022-05-13 2024-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 雙股ｄｎａ組合物及相關方法
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
CA3256897A1 (fr) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation
WO2023235725A2 (fr) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Agents thérapeutiques à base de crispr pour une maladie d'expansion de répétition c9orf72
JP2025521154A (ja) 2022-05-31 2025-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法
JP2023181989A (ja) * 2022-06-13 2023-12-25 上海臻上医薬科技有限公司 マイクロニードル注射製剤およびその使用
CN119384498A (zh) 2022-06-16 2025-01-28 因特利亚治疗公司 用于对细胞进行遗传修饰的方法和组合物
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024006955A1 (fr) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Lymphocytes t modifiés
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
EP4565604A2 (fr) 2022-08-01 2025-06-11 Flagship Pioneering Innovations VII, LLC Protéines immunomodulatrices et méthodes associées
WO2024035952A1 (fr) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs
WO2024061296A2 (fr) 2022-09-22 2024-03-28 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions et méthodes de traitement de l'hypercholestérolémie et/ou d'une maladie cardiovasculaire
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
EP4612296A1 (fr) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
EP4612184A1 (fr) 2022-11-04 2025-09-10 Regeneron Pharmaceuticals, Inc. Protéines de liaison de sous-unité auxiliaire gamma 1 du canal calcique dépendant de la tension (cacng1) et administration médiée par cacng1 au muscle squelettique
TW202434728A (zh) 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
WO2024102434A1 (fr) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Compositions d'arn comprenant des nanoparticules lipidiques ou des packs de messagers naturels reconstitués en packs lipidiques
KR20250116795A (ko) 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
CN118236344A (zh) * 2022-12-15 2024-06-25 深圳瑞吉生物科技有限公司 一种核酸脂质纳米载体及其制备方法与应用
WO2024134511A2 (fr) * 2022-12-20 2024-06-27 Seqirus Inc. Composition de nanoparticules lipidiques
EP4638783A2 (fr) 2022-12-22 2025-10-29 Intellia Therapeutics, Inc. Procédés d'analyse de cargos d'acides nucléiques d'ensembles d'acides nucléiques lipidiques
CN120418427A (zh) 2022-12-23 2025-08-01 因特利亚治疗公司 用于基因组编辑的系统和方法
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
WO2024151673A2 (fr) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation de plaies
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151583A2 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
WO2024167885A1 (fr) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Compositions immunomodulatrices et procédés associés
CN121263425A (zh) 2023-02-13 2026-01-02 旗舰创业创新第七有限责任公司 含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体
EP4665405A1 (fr) 2023-02-17 2025-12-24 Flagship Pioneering Innovations VII, LLC Compositions d'adn comprenant un uracile modifié
IL322378A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA compositions containing modified cytosine
CN121358494A (zh) 2023-03-15 2026-01-16 旗舰创业创新第六有限责任公司 免疫原性组合物及其用途
EP4680750A1 (fr) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides et leurs utilisations
EP4695391A1 (fr) 2023-04-12 2026-02-18 Flagship Pioneering Innovations VI, LLC Trems destinés à être utilisés dans la correction de mutations faux-sens
EP4695393A1 (fr) 2023-04-12 2026-02-18 Flagship Pioneering Innovations VI, LLC Trem modifiées, compositions et procédés associés
WO2024220746A2 (fr) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Agents d'arni ciblant la synthase d'acides gras et procédés associés
WO2024258829A1 (fr) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Compositions de vaccin contre le sars-cov-2 et procédés associés
WO2024259135A1 (fr) 2023-06-13 2024-12-19 Intellia Therapeutics, Inc. Dosages pour l'analyse de molécules d'acide ribonucléique (arn)
WO2025006684A1 (fr) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
KR20260032927A (ko) 2023-06-30 2026-03-10 리제너론 파마슈티칼스 인코포레이티드 상동성 지향 복구를 증가시키는 방법 및 조성물
KR20260044217A (ko) 2023-07-25 2026-04-01 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 Cas 엔도뉴클레아제 및 관련 방법
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
CN121693566A (zh) 2023-07-28 2026-03-17 瑞泽恩制药公司 使用bGH-SV40L串联PolyA在单向基因插入期间增强转基因表达
WO2025038646A1 (fr) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions car-t cd70 et méthodes de thérapie à base de cellules
IL326191A (en) 2023-08-14 2026-03-01 Intellia Therapeutics Inc Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038637A1 (fr) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions et procédés de modification génétique du récepteur bêta du facteur de croissance transformant de type 2 (tgfβr2)
WO2025038642A1 (fr) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions et procédés de modification génétique de cd70
WO2025042786A1 (fr) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
WO2025049481A1 (fr) 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Procédés d'édition in vitro d'un gène hla-a
CN121752723A (zh) * 2023-08-31 2026-03-27 正基基因科技有限公司 编码crispr相关蛋白的核酸及其应用
WO2025054236A2 (fr) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Compositions de vaccin contre le sars-cov-2 et procédés associés
WO2025064401A1 (fr) 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Produit d'adn simple brin résistant aux nucléases pour administration non virale à une cellule et ses procédés de production
WO2025064396A1 (fr) 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Produit d'adn double brin résistant aux nucléases pour administration non virale à une cellule et ses procédés de production
WO2025064475A2 (fr) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques
WO2025072331A1 (fr) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Nucléases cas et procédés ou méthodes associés
WO2025096807A2 (fr) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Nouvelles formes d'adn thérapeutique
WO2025106670A1 (fr) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (fr) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Nucléases cas et méthodes associées
WO2025128871A2 (fr) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition de gènes et en tant que vaccins et agents thérapeutiques
WO2025137301A1 (fr) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Procédés d'ingénierie rapide de cellules
WO2025137439A2 (fr) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Lymphocytes t modifiés
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025194019A1 (fr) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Méthodes de traitement de la fibrose hépatique et de la stéatose hépatique non alcoolique
WO2025217275A2 (fr) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Compositions ciblées sur des cellules immunitaires et procédés associés
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025240946A1 (fr) 2024-05-17 2025-11-20 Intellia Therapeutics, Inc. Nanoparticules lipidiques et composition de nanoparticules lipidiques
WO2025245188A2 (fr) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Méthodes de traitement de la stéatose hépatique et d'une stéatose hépatique non alcoolique
WO2025245111A1 (fr) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Protéines de ciblage d'immunorécepteurs et procédés associés
WO2025255308A1 (fr) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Polypeptides chimériques du co-récepteur cd8 dans une thérapie par cellules tcr
WO2025265017A1 (fr) 2024-06-20 2025-12-26 Regeneron Pharmaceuticals, Inc. Insertion de gène ass1 pour le traitement de la citrullinémie de type i
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026003582A2 (fr) 2024-06-27 2026-01-02 Axelyf ehf. Lipides et nanoparticules lipidiques
WO2026055543A1 (fr) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Compositions d'adn modifiées et procédés associés
WO2026055547A1 (fr) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Compositions d'adn et procédés associés
WO2026064313A1 (fr) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Compositions d'arn et procédés associés
WO2026085300A1 (fr) 2024-10-16 2026-04-23 Flagship Pioneering Innovations Vii, Llc Procédés et compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009891C (fr) 2009-12-23 2020-09-15 Novartis Ag Lipides, compositions lipidiques, et procedes d'utilisation associes
US8691750B2 (en) * 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2014093655A2 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Fabrication et optimisation de systèmes, de procédés et de compositions pour la manipulation de séquence avec des domaines fonctionnels
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
CN105143456A (zh) * 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
CA2917348A1 (fr) * 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprenant des polynucleotides synthetiques codant pour des proteines liees a crispr et des arnsg synthetiques et methodes d'utilisation
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3470089A1 (fr) * 2013-12-12 2019-04-17 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques des systèmes et compositions crispr-cas pour cibler les troubles et les maladies au moyen de composants d'administration de particules
EP3083556B1 (fr) 2013-12-19 2019-12-25 Novartis AG Lipides et compositions lipidiques pour le largage d'agents actifs
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
EP3275448B1 (fr) 2015-03-24 2025-10-29 Kyowa Kirin Co., Ltd. Nanoparticules lipidiques contenant des acides nucléiques
WO2016197133A1 (fr) 2015-06-04 2016-12-08 Protiva Biotherapeutics, Inc. Administration d'agents thérapeutiques crispr avec des nanoparticules de lipide
US20190054112A1 (en) * 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
CN109715801B (zh) * 2015-12-01 2022-11-01 克里斯普治疗股份公司 用于治疗α1抗胰蛋白酶缺乏的材料和方法
KR20180118111A (ko) 2015-12-23 2018-10-30 크리스퍼 테라퓨틱스 아게 근위축성 측색 경화증 및/또는 전두측두엽 퇴행의 치료 물질 및 방법
EP3405579A1 (fr) * 2016-01-22 2018-11-28 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
LT3436077T (lt) * 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
TWI851534B (zh) * 2016-12-22 2024-08-11 美商英特利亞醫療公司 用於治療α-１抗胰蛋白酶缺乏症之組合物及方法

Also Published As

Publication number Publication date
FI3688162T3 (fi) 2024-05-15
JP2020536125A (ja) 2020-12-10
TW201924724A (zh) 2019-07-01
HUE066630T2 (hu) 2024-08-28
SMT202400172T1 (it) 2024-07-09
SG11202002653UA (en) 2020-04-29
AR113031A1 (es) 2020-01-15
AU2024224004A1 (en) 2024-10-24
WO2019067992A1 (fr) 2019-04-04
IL320823A (en) 2025-07-01
CA3077413A1 (fr) 2019-04-04
IL273541A (en) 2020-05-31
JP7645929B2 (ja) 2025-03-14
RS65493B1 (sr) 2024-05-31
IL273541B1 (en) 2025-06-01
SA520411636B1 (ar) 2024-06-09
SI3688162T1 (sl) 2024-06-28
JP2023103421A (ja) 2023-07-26
IL273541B2 (en) 2025-10-01
KR20250042147A (ko) 2025-03-26
LT3688162T (lt) 2024-05-27
AU2018338915B2 (en) 2024-10-24
EP3688162A1 (fr) 2020-08-05
MX2024013597A (es) 2024-12-06
PL3688162T3 (pl) 2024-06-10
EP3688162B1 (fr) 2024-03-06
JP7284179B2 (ja) 2023-05-30
AU2018338915C1 (en) 2025-05-08
PT3688162T (pt) 2024-04-23
UA129257C2 (uk) 2025-03-05
MX2020007148A (es) 2020-10-08
JP2025084955A (ja) 2025-06-03
MY204993A (en) 2024-09-26
US20230140670A1 (en) 2023-05-04
PH12020552306A1 (en) 2023-07-17
DK3688162T3 (da) 2024-05-13
EP4385514A2 (fr) 2024-06-19
EP4385514A3 (fr) 2024-10-23
CN111406108A (zh) 2020-07-10
TWI833708B (zh) 2024-03-01
AU2018338915A1 (en) 2020-04-23
KR20200079497A (ko) 2020-07-03
EA202090868A1 (ru) 2020-09-16
BR112020006300A2 (pt) 2020-10-20
HRP20240627T1 (hr) 2024-08-02

Similar Documents

Publication Publication Date Title
ES2980114T3 (es) Formulaciones
JP7581405B2 (ja) Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤
EP3688173B1 (fr) Méthode in vitro d'administration d'arnm à l'aide de nanoparticules lipidiques
HK40112168A (en) Formulations
HK40025999B (en) Formulations
HK40025999A (en) Formulations
EA047139B1 (ru) Составы
HK40129152A (en) Lipid nanoparticle formulations for crispr/cas components
HK40033101A (en) Formulations
HK40025136B (en) In vitro method of mrna delivery using lipid nanoparticles
HK40025136A (en) In vitro method of mrna delivery using lipid nanoparticles
HK40067192A (zh) 用於多肽表达的多核苷酸、组合物和方法
HK40003257A (en) Lipid nanoparticle formulations for crispr/cas components
HK40003257B (en) Lipid nanoparticle formulations for crispr/cas components
HK40005508A (en) Lipid nanoparticle formulations for crispr/cas components